• / Free eNewsletters & Magazine
  • / My Account
Home>Stocks>Exelixis

Exelixis

  1. All
  2. Morningstar Articles
  3. 3rd Party
  4. Investing
  1. venBio Sends Letter to Immunomedics Stockholders

    venBio Sends Letter to Immunomedics Stockholders

  2. Exelixis and Takeda Enter into Exclusive Licensing Agreement to Commercialize and Develop Novel Cancer Therapy Cabozantinib in Japan

    Exelixis and Takeda Enter into Exclusive Licensing Agreement to Commercialize and Develop Novel Cancer Therapy Cabozantinib in Japan

  3. Ipsen Delivers Strong 2016 Results and Expects Further Sales Growth and Margin Enhancement for 2017

    Ipsen Delivers Strong 2016 Results and Expects Further Sales Growth and Margin Enhancement for 2017

  4. venBio Comments on Immunomedics Partnership Announcement

    venBio Comments on Immunomedics Partnership Announcement

  5. Top 10 High Growth Composite Material Market by Resin Type, Fiber Type, Application & Region - Global Forecasts to 2021 - Expected to Reach $105.26 Billion - Research and Markets

    Top 10 High Growth Composite Material Market by Resin Type, Fiber Type, Application & Region - Global Forecasts to 2021 - Expected to Reach $105.26 Billion - Research and Markets

  6. Is This the Year Exelixis Excels?

    The lack of early success in its lead drug's cancer trial scares the market, but we see a buying opportunity.

  7. Breakthrough Therapies: Market Dynamics and Investment Opportunities - Should Reach $99.2 Billion by 2022 - Research and Markets

    Breakthrough Therapies: Market Dynamics and Investment Opportunities - Should Reach $99.2 Billion by 2022 - Research and Markets

  8. Global Sealants and Sealant Applicators Technologies Market Report 2017-2021: $26.4 Billion Market Dynamics, Growth Drivers, Restraints, and Opportunities - Research and Markets

    Global Sealants and Sealant Applicators Technologies Market Report 2017-2021: $26.4 Billion Market Dynamics, Growth Drivers, Restraints, and Opportunities - Research and Markets

  9. Beware 5-Star Stocks Bearing No Moats

    Lack of competitive advantages may mean these companies aren't the bargains they seem to be.

  10. Don't Bail on Biotech

    We see opportunity as fleeing investors trigger an irrational sell-off.

12

©2017 Morningstar Advisor. All right reserved.